Skip to main content

View full-text article in PMC

. 2013 Jul 23;8(7):e69039. doi: 10.1371/journal.pone.0069039

Table 5. Tumor site- and tumor-node-metastasis stage-specific hazard ratios for the associations between the XRCC1 Arg399Gln and XPD Lys751Gln allelic variants and overall survival among colorectal cancer patients.

	Colon						Rectum
	Stage II/III			Stage IV			Stage II/III			Stage IV
Variables	HR (95% CI)^a	P	FDR	HR (95% CI)^a	P	FDR	HR (95% CI)^a	P	FDR	HR (95% CI)^a	P	FDR
XRCC1 Arg399Gln
Arg/Gln+Gln/Gln vs Arg/Arg	1.69 (1.06–2.71)	0.028	0.252	1.05 (0.67–1.66)	0.829	0.933	1.15 (0.67–1.96)	0.612	0.918	0.93 (0.55–1.59)	0.794	0.933
XPD Lys751Gln
Lys/Gln+Gln/Gln vs Lys/Lys	1.28 (0.72–2.26)	0.403	0.727	1.00 (0.54–1.85)	0.999	0.999	1.57 (0.88–2.81)	0.125	0.375	1.98 (0.94–4.17)	0.072	0.324

^a

Adjusted for age and sex.

HR: hazard ratio; CI: confidence interval; FDR: false discovery rate.